Financial Gravity Asset Management’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.91M Sell
77,066
-1,471
-2% -$68.6K 0.7% 38
2025
Q4
$2.32M Buy
78,537
+8,212
+12% +$223K 0.45% 60
2025
Q3
$1.82M Buy
+70,325
New +$1.96M 0.36% 63
2025
Q1
$1.28M Buy
+45,064
New +$1.6M 0.28% 73
2024
Q2
$2.16M Buy
18,191
+946
+5% +$120K 0.54% 47
2024
Q1
$1.72M Buy
17,245
+2
+0% +$202 0.48% 52
2023
Q4
$1.71M Buy
+17,243
New +$1.45M 0.48% 52
2021
Q3
$1.53M Sell
3,016
-4,385
-59% -$1.62M 0.72% 27
2021
Q2
$1.97M Buy
+7,401
New +$1.32M 0.71% 28

Other funds holding MRNA

Financial Gravity Asset Management's MRNA Position: Q1 2026 in Review

Financial Gravity Asset Management reduced its Moderna (MRNA) stake by 1.9% in Q1 2026, selling an estimated $68.6K and leaving 77,066 shares worth $3.91M. The position accounts for 0.7% of the portfolio, ranked #38.

Financial Gravity Asset Management first reported a position in MRNA in Q2 2021 and has held it in 9 quarters since. 725 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Financial Gravity Asset Management held 77,066 shares of Moderna worth $3.91M as of Q1 2026.
  • Financial Gravity Asset Management sold 1,471 Moderna shares in Q1 2026, an estimated $68.6K.
  • Moderna made up 0.7% of Financial Gravity Asset Management's portfolio in Q1 2026, its #38 holding.
  • Financial Gravity Asset Management first reported a position in Moderna in Q2 2021 and has held it in 9 quarters since.
  • 725 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Financial Gravity Asset Management's 13F filing for Q1 2026, filed 8 May 2026.